论文部分内容阅读
2004年12月20日哈药集团公告：母公司哈药集团有限公司向哈药集团股份有限公司其他所有股东发出全面收购要约。要约价格5.08元／股，数量81029.96万股，占总股本的65.24％。 此前，哈药母公司的实际控制人哈尔滨市国资委已于12月14日与中信资本投资有限公司、美国华平投资集团、黑龙江辰能哈工大高科技风险投资有限公司等共同签订了《重组增资协议》，三家投资方以现金人民币20.35亿元对母公司进行增资，同时以所持哈药股票作抵押，哈药母公司向中信信托借款7.8亿元。
December 20, 2004 Harbin Pharmaceutical Group Notice: The parent company Harbin Pharmaceutical Group Co., Ltd. issued a general offer to all other shareholders of Harbin Pharmaceutical Group Co., Ltd. The offer price 5.08 yuan / share, the number of 810299600 shares, accounting for 65.24% of the total share capital. Prior to this, Harbin SASAC, the actual controller of the Harbin Pharmaceutical Parent Company, signed the “Restructuring Capital Increase” on December 14 with CITIC Capital Investment Co., Ltd., the United States Warburg Pincus Group, Heilongjiang Chenneng High-tech Venture Capital Co., Ltd., Agreement ", the three investors in cash of 2.035 billion yuan to the parent company to increase their capital, while the shares held by Harbin Pharmaceutical as a security, Harbin Pharmaceutical parent company to borrow 0.78 billion from CITIC Trust.